{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T16:39:56Z","timestamp":1793637596966,"version":"4.5.1"},"reference-count":33,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,5,9]],"date-time":"2024-05-09T00:00:00Z","timestamp":1715212800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca plc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["annalsofoncology.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1016\/j.annonc.2024.04.012","type":"journal-article","created":{"date-parts":[[2024,5,8]],"date-time":"2024-05-08T12:26:47Z","timestamp":1715171207000},"page":"707-717","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":58,"title":["A phase I dose escalation and expansion trial of the next-generation oral SERD camizestrant in women with ER-positive, HER2-negative advanced breast cancer: SERENA-1 monotherapy results"],"prefix":"10.1016","volume":"35","author":[{"given":"E.","family":"Hamilton","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Oliveira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Turner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Garc\u00eda-Corbacho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Hernando","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.M.","family":"Ciruelos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Kabos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Ruiz-Borrego","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Armstrong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.R.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Vaklavas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Twelves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Boni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Incorvati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Brier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Gibbons","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Klinowska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.P.O.","family":"Lindemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.J.","family":"Morrow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Sykes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.D.","family":"Baird","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.annonc.2024.04.012_bib1","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"10.1016\/j.annonc.2024.04.012_bib2","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3322\/caac.21763","article-title":"Cancer statistics, 2023","volume":"73","author":"Siegel","year":"2023","journal-title":"CA Cancer J Clin"},{"issue":"6","key":"10.1016\/j.annonc.2024.04.012_bib3","doi-asserted-by":"crossref","first-page":"524","DOI":"10.3322\/caac.21754","article-title":"Breast cancer statistics, 2022","volume":"72","author":"Giaquinto","year":"2022","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.annonc.2024.04.012_bib4","series-title":"Breast Cancer Facts & Figures\u00a02022-2024","year":"2022"},{"issue":"10","key":"10.1016\/j.annonc.2024.04.012_bib5","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1038\/nrclinonc.2015.117","article-title":"ESR1 mutations\u2014a mechanism for acquired endocrine resistance in breast cancer","volume":"12","author":"Jeselsohn","year":"2015","journal-title":"Nat Rev Clin Oncol"},{"issue":"3","key":"10.1016\/j.annonc.2024.04.012_bib6","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1038\/s41416-018-0354-9","article-title":"The oral selective oestrogen receptor degrader (SERD) AZD9496 is comparable to fulvestrant in antagonising ER and circumventing endocrine resistance","volume":"120","author":"Nardone","year":"2019","journal-title":"Br J Cancer"},{"issue":"7","key":"10.1016\/j.annonc.2024.04.012_bib7","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/S0959-8049(02)00810-9","article-title":"The use of gonadotrophin-releasing hormone (GnRH) agonists in early and advanced breast cancer in pre- and perimenopausal women","volume":"39","author":"Robertson","year":"2003","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.annonc.2024.04.012_bib8","series-title":"Hormone Therapy for Breast Cancer","year":"2020"},{"issue":"suppl 2","key":"10.1016\/j.annonc.2024.04.012_bib9","doi-asserted-by":"crossref","first-page":"S60","DOI":"10.1016\/j.breast.2015.07.015","article-title":"The changing role of ER in endocrine resistance","volume":"24","author":"Nardone","year":"2015","journal-title":"Breast"},{"issue":"2","key":"10.1016\/j.annonc.2024.04.012_bib10","first-page":"408","article-title":"Investigation of a new pure antiestrogen (ICI 182780) in women with primary breast cancer","volume":"54","author":"DeFriend","year":"1994","journal-title":"Cancer Res"},{"issue":"4","key":"10.1016\/j.annonc.2024.04.012_bib11","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1002\/1097-0142(20000815)89:4<817::AID-CNCR14>3.0.CO;2-6","article-title":"ICI 182,780 (Faslodex): development of a novel, \u201cpure\u201d antiestrogen","volume":"89","author":"Howell","year":"2000","journal-title":"Cancer"},{"issue":"5.5","key":"10.1016\/j.annonc.2024.04.012_bib12","first-page":"552","article-title":"NCCN Guidelines updates: breast cancer","volume":"17","author":"Telli","year":"2019","journal-title":"J\u00a0Natl Compr Canc Netw"},{"issue":"suppl 2","key":"10.1016\/j.annonc.2024.04.012_bib13","first-page":"11","article-title":"ICI 182,780 (Fulvestrant)\u2014the first oestrogen receptor down-regulator\u2014current clinical data","volume":"85","author":"Robertson","year":"2001","journal-title":"Br J Cancer"},{"issue":"16","key":"10.1016\/j.annonc.2024.04.012_bib14","doi-asserted-by":"crossref","first-page":"4242","DOI":"10.1158\/1078-0432.CCR-19-3387","article-title":"A\u00a0randomized, open-label, presurgical, window-of-opportunity study comparing the pharmacodynamic effects of the novel oral SERD AZD9496 with fulvestrant in patients with newly diagnosed ER(+) HER2(-) primary breast cancer","volume":"26","author":"Robertson","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"16","key":"10.1016\/j.annonc.2024.04.012_bib15","doi-asserted-by":"crossref","first-page":"4793","DOI":"10.1158\/1078-0432.CCR-16-2561","article-title":"Elacestrant (RAD1901), a selective estrogen receptor degrader (SERD), has antitumor activity in multiple ER(+) breast cancer patient-derived xenograft models","volume":"23","author":"Bihani","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.annonc.2024.04.012_bib16","first-page":"S88","article-title":"Giredestrant (GDC-9545) vs physician choice of endocrine monotherapy (PCET) in patients (pts) with ER+, HER2\u2013 locally advanced\/metastatic breast cancer (LA\/mBC): primary analysis of the phase II, randomised, open-label acelERA BC study","volume":"33","author":"Jimenez","year":"2022","journal-title":"Ann Oncol"},{"issue":"suppl 15","key":"10.1016\/j.annonc.2024.04.012_bib17","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1200\/JCO.2021.39.15_suppl.1050","article-title":"A\u00a0phase 1a\/b trial of imlunestrant (LY3484356), an oral selective estrogen receptor degrader (SERD) in ER-positive (ER+) advanced breast cancer (aBC) and endometrial endometrioid cancer (EEC): monotherapy results from EMBER","volume":"39","author":"Jhaveri","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.annonc.2024.04.012_bib18","unstructured":"Sanofi provides update on phase 2 study evaluating amcenestrant in ER+\/HER2- advanced or metastatic breast cancer. https:\/\/www.sanofi.com\/en\/media-room\/press-releases\/2022\/2022-03-14-06-00-00-2402216. Accessed January 18, 2024."},{"issue":"24","key":"10.1016\/j.annonc.2024.04.012_bib19","doi-asserted-by":"crossref","first-page":"4014","DOI":"10.1200\/JCO.22.02746","article-title":"AMEERA-3: randomized phase II study of amcenestrant (oral selective estrogen receptor degrader) versus standard endocrine monotherapy in estrogen receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer","volume":"41","author":"Tolaney","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.annonc.2024.04.012_bib20","unstructured":"AstraZeneca press release. Camizestrant significantly improved progression-free survival vs. Faslodex in SERENA-2 Phase II trial in advanced ER-positive breast cancer (astrazeneca.com). https:\/\/www.astrazeneca.com\/media-centre\/press-releases\/2022\/camizestrant-significantly-improved-progression-free-survival.html. Accessed October 26, 2022."},{"issue":"23","key":"10.1016\/j.annonc.2024.04.012_bib21","doi-asserted-by":"crossref","first-page":"3989","DOI":"10.1158\/0008-5472.CAN-23-0694","article-title":"The next-generation oral selective estrogen receptor degrader camizestrant (AZD9833) suppresses ER+ breast cancer growth and overcomes endocrine and CDK4\/6 inhibitor resistance","volume":"83","author":"Lawson","year":"2023","journal-title":"Cancer Res"},{"issue":"13","key":"10.1016\/j.annonc.2024.04.012_bib22","doi-asserted-by":"crossref","first-page":"2420","DOI":"10.1002\/sim.3230","article-title":"Critical aspects of the Bayesian approach to phase I cancer trials","volume":"27","author":"Neuenschwander","year":"2008","journal-title":"Stat Med"},{"issue":"2","key":"10.1016\/j.annonc.2024.04.012_bib23","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"issue":"4","key":"10.1016\/j.annonc.2024.04.012_bib24","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1158\/1078-0432.CCR-15-1627-T","article-title":"Bias-corrected targeted next-generation sequencing for rapid, multiplexed detection of actionable alterations in cell-free DNA from advanced lung cancer patients","volume":"22","author":"Paweletz","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"3","key":"10.1016\/j.annonc.2024.04.012_bib25","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1021\/acs.jmedchem.8b01837","article-title":"Tricyclic indazoles\u2014a novel class of selective estrogen receptor degrader antagonists","volume":"62","author":"Scott","year":"2019","journal-title":"J\u00a0Med Chem"},{"key":"10.1016\/j.annonc.2024.04.012_bib26","article-title":"P-174-Randomized open-label study to assess relative bioavailability of different oral formulations, the effect of food on absorption and absolute bioavailability of AZD9833 (camizestrant) in post-menopausal healthy female volunteers","author":"Sykes","year":"2022","journal-title":"USA: American Society for Clinical Pharmacology and Therapeutics (ASCPT)"},{"issue":"28","key":"10.1016\/j.annonc.2024.04.012_bib27","doi-asserted-by":"crossref","first-page":"3246","DOI":"10.1200\/JCO.22.00338","article-title":"Elacestrant (oral selective estrogen receptor degrader) versus standard endocrine therapy for estrogen receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: results from the randomized phase III EMERALD trial","volume":"40","author":"Bidard","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"issue":"suppl 16","key":"10.1016\/j.annonc.2024.04.012_bib28","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1200\/JCO.2023.41.16_suppl.1066","article-title":"Clinical activity of camizestrant, a next-generation SERD, versus fulvestrant in patients with a detectable ESR1 mutation: exploratory analysis of the SERENA-2 phase 2 trial. 2023","volume":"41","author":"Oliviera","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"issue":"suppl 16","key":"10.1016\/j.annonc.2024.04.012_bib29","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1200\/JCO.2022.40.16_suppl.1032","article-title":"Serena-1: Updated analyses from a phase 1 study (parts C\/D) of the next-generation oral SERD camizestrant (AZD9833) in combination with palbociclib, in women with ER-positive, HER2-negative advanced breast cancer","volume":"40","author":"Oliviera","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.annonc.2024.04.012_bib30","unstructured":"ClinicalTrials.gov NCT04711252. A comparative study of AZD9833 plus palbociclib versus anastrozole plus palbociclib in patients with ERpositive HER2 negative breast cancer who have not received any systemic treatment for advanced disease (SERENA-4). https:\/\/clinicaltrials.gov\/study\/NCT04711252. Accessed January 18, 2024."},{"key":"10.1016\/j.annonc.2024.04.012_bib31","unstructured":"ClinicalTrials.gov NCT04964934. Phase III study to assess AZD9833\u00fe CDK4\/6 inhibitor in HR\u00fe\/HER2-MBC with detectable ESR1m before progression (SERENA-6). https:\/\/clinicaltrials.gov\/study\/NCT04964934. Accessed January 18, 2024."},{"key":"10.1016\/j.annonc.2024.04.012_bib32","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.SABCS22-P3-07-28","article-title":"Abstract P3-07-28: SERENA-1: updated analyses from a phase 1 study of the next generation oral selective estrogen receptor degrader camizestrant (AZD9833) combined with abemaciclib, in women with ER-positive, HER2-negative advanced breast cancer","volume":"83","author":"Turner","year":"2023","journal-title":"Cancer Res"},{"key":"10.1016\/j.annonc.2024.04.012_bib33","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.SABCS23-PO3-19-09","article-title":"SERENA-1: results from a phase 1 study (Parts I\/J) testing the next-generation oral selective estrogen receptor degrader (ngSERD) camizestrant (AZD9833) in combination with capivasertib in women with ER-positive, HER2- negative advanced breast cancer","volume":"84","author":"Vaklavas","year":"2024","journal-title":"Cancer Res."}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753424001388?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753424001388?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,7,22]],"date-time":"2024-07-22T22:03:19Z","timestamp":1721685799000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753424001388"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":33,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["S0923753424001388"],"URL":"https:\/\/doi.org\/10.1016\/j.annonc.2024.04.012","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A phase I dose escalation and expansion trial of the next-generation oral SERD camizestrant in women with ER-positive, HER2-negative advanced breast cancer: SERENA-1 monotherapy results","name":"articletitle","label":"Article Title"},{"value":"Annals of Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.annonc.2024.04.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}]}}